Novartis Ag NVS
NYSE NVS
$140.35 -0.58 (-0.41%)
At close: Sep 18, 2026 · 4:00 PM EDT

Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2026)

Novartis Ag's (NVS) quarterly Income from Non-Controlling Interests came in at -$7.0 million in Q2 2026, up 58.82% year-over-year from -$4.4 million in Q2 2025, and up 50.0% quarter-over-quarter from -$14.0 million in Q4 2025.

Analysis

Novartis Ag (NVS) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Novartis Ag has disclosed Income from Non-Controlling Interests across 18 years of filings, most recently posting -$7.0 million for Q2 2026.

  • In Q2 2026, Income from Non-Controlling Interests rose 58.82% year-over-year to -$7.0 million; the TTM figure through Jun 2026 stood at -$19.0 million (down 18.75% YoY), while the FY2025 annual figure was -$17.0 million, down 750.0% from the prior year.
  • Income from Non-Controlling Interests came in at -$7.0 million for Q2 2026 at Novartis Ag, up from -$14.0 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $3.0 million in Q1 2025 to a low of -$17.0 million in Q2 2025.
  • Average Income from Non-Controlling Interests over 5 years is -$2.1 million, with a median of $1.0 million recorded in 2022.
  • Year-over-year, Income from Non-Controlling Interests soared 200.0% in 2022 and slumped 800.0% in 2025.
  • Over 5 years, Income from Non-Controlling Interests stood at -$2.0 million in 2022, then soared by 200.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then tumbled by 800.0% to -$14.0 million in 2025, then surged by 50.0% to -$7.0 million in 2026.
  • Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$7.0 million in Q2 2026, -$14.0 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn -
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn 3.00 Mn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn -2.00 Mn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn -7.00 Mn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn 10.00 Mn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn -1.00 Mn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn 39.52 Mn
8 Revolution Medicines 40.91 Bn 40.91 Bn - -
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn -
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -7.00 Mn
Dec 31, 2025 -14.00 Mn
Sep 30, 2025 2.00 Mn
Jun 30, 2025 -17.00 Mn
Mar 31, 2025 3.00 Mn
Dec 31, 2024 2.00 Mn
Sep 30, 2024 -4.00 Mn
Dec 31, 2023 2.00 Mn
Sep 30, 2023 2.00 Mn
Jun 30, 2023 1.00 Mn
Mar 31, 2023 1.00 Mn
Dec 31, 2022 -2.00 Mn
Sep 30, 2022 2.00 Mn
Jun 30, 2022 1.00 Mn
Mar 31, 2022 -3.00 Mn
Dec 31, 2021 -2.00 Mn
Jun 30, 2021 -1.00 Mn
Dec 31, 2020 5.00 Mn
Sep 30, 2020 -3.00 Mn
Mar 31, 2020 -3.00 Mn